

# Walter Taal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5043632/publications.pdf>

Version: 2024-02-01

43  
papers

4,120  
citations

304743

22  
h-index

254184

43  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4951  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. <i>Lancet Oncology, The</i> , 2008, 9, 453-461.	10.7	990
2	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	27.0	670
3	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 943-953.	10.7	639
4	Incidence of early pseudoâ€ progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. <i>Cancer</i> , 2008, 113, 405-410.	4.1	403
5	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	13.7	307
6	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Oncology, The</i> , 2021, 22, 813-823.	10.7	132
7	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020, 21, e305-e316.	10.7	115
8	GABA and glycine frequently colocalize in terminals on cat spinal motoneurons. <i>NeuroReport</i> , 1994, 5, 2225-2228.	1.2	93
9	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016, 76, 525-534.	0.9	93
10	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. <i>Neuro-Oncology</i> , 2011, 13, 235-241.	1.2	60
11	Chemotherapy in glioma. <i>CNS Oncology</i> , 2015, 4, 179-192.	3.0	58
12	Clinical management of spinal metastasesâ€ The Dutch national guideline. <i>European Journal of Cancer</i> , 2018, 104, 81-90.	2.8	48
13	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. <i>European Journal of Cancer</i> , 2015, 51, 1321-1330.	2.8	45
14	Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now194.	1.2	45
15	Dose dense 1Âweek on/1Âweek off temozolomide in recurrent glioma: a retrospective study. <i>Journal of Neuro-Oncology</i> , 2012, 108, 195-200.	2.9	34
16	Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumabâ€ a report from the BELOB trial. <i>Neuro-Oncology</i> , 2017, 19, 853-861.	1.2	34
17	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	1.2	34
18	Worries and needs of adults and parents of adults with neurofibromatosis type 1. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 1150-1160.	1.2	32

#	ARTICLE	IF	CITATIONS
19	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	7.7	32
20	Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. <i>Journal of Neuro-Oncology</i> , 2015, 121, 365-372.	2.9	31
21	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	7.0	27
22	Is motor inhibition during laughter due to emotional or respiratory influences?. <i>Psychophysiology</i> , 2004, 41, 254-258.	2.4	26
23	MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. <i>Journal of Neuro-Oncology</i> , 2011, 101, 405-417.	2.9	25
24	A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 5	1.2	20
25	The Dutch national guideline on metastases and hematological malignancies localized within the spine; a multidisciplinary collaboration towards timely and proactive management. <i>Cancer Treatment Reviews</i> , 2018, 69, 29-38.	7.7	19
26	Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. <i>PLoS ONE</i> , 2017, 12, e0183155.	2.5	12
27	Are we done with dose-intense temozolomide in recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2014, 16, 1161-1163.	1.2	11
28	Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. <i>Supportive Care in Cancer</i> , 2012, 20, 1639-1647.	2.2	10
29	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763.	1.1	9
30	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. <i>Scientific Reports</i> , 2020, 10, 2927.	3.3	8
31	A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021, 23, 557-571.	1.2	8
32	The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis. <i>Neuro-Oncology</i> , 2022, 24, 429-441.	1.2	7
33	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. <i>Neuro-Oncology Practice</i> , 2022, 9, 310-316.	1.6	7
34	Attention and Motor Learning in Adult Patients with Neurofibromatosis Type 1. <i>Journal of Attention Disorders</i> , 2022, 26, 563-572.	2.6	6
35	A woman with multiple sclerosis and pink saliva. <i>Lancet Neurology</i> , The, 2003, 2, 254-255.	10.2	5
36	Motor cortical excitability and plasticity in patients with neurofibromatosis type 1. <i>Clinical Neurophysiology</i> , 2020, 131, 2673-2681.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. <i>Neuro-Oncology</i> , 2022, 24, 326-328.	1.2	5
38	Bevacizumab alone or in combination with chemotherapy in glioblastomas?â€“Authors' reply. <i>Lancet Oncology</i> , The, 2014, 15, e473-e474.	10.7	3
39	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdb145.	0.7	3
40	Diagnostic value of 18F-FDG PET-CT in detecting malignant peripheral nerve sheath tumors among adult and pediatric neurofibromatosis type 1 patients. <i>Journal of Neuro-Oncology</i> , 2022, 156, 559-567.	2.9	3
41	The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology Advances</i> , 2022, 4, vdb032.	0.7	1
42	Rare CNS tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas and intracranial germ cell tumors. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	0
43	Evaluation of an online tool about the expected course of disease for glioblastoma patients â€“ a qualitative study. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	0